MAC Lung Disease clinical trials at UCSF
2 in progress, 1 open to eligible people
MAC lung disease is a serious lung infection caused by bacteria. UCSF is running a study to evaluate the safety and effectiveness of Clofazimine Inhalation Suspension. This research could lead to new treatment methods for managing MAC lung disease.
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
open to eligible people ages 18-85
This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
Fresno, California and other locations
Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Sorry, in progress, not accepting new patients
This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. This study will enroll adult patients with treatment-refractory MAC lung disease who meet all eligibility criteria (including clinical, radiographic, and microbiological criteria).
San Francisco, California and other locations
Our lead scientists for MAC Lung Disease research studies include Mohamed Fayed, MD, FCCP.
Last updated: